Liquid biopsies are quickly evolving beyond ctDNA, but technical challenges remain
Newly-presented studies highlight that insights into cancer can also be unlocked from circulating tumour cells, exosomal microRNA and cell-free RNA
Growing evidence supports the use of ctDNA as a biomarker in colon cancer
Data from clinical trials show the value of liquid biopsy in treatment decision-making and prognostication
NGS – a weapon in molecular pathology?
Next generation sequencing has revolutionised cancer management, but has also raised some issues that have yet to be addressed